Both in Diagnostics
Myriad Genetics vs Intellia Therapeutics
Over the past year MYGN returned −27.0% and NTLA returned −5.0%; their daily moves had a correlation of 0.25.
MYGN −27.0% NTLA −5.0%Growth of $1, one year, split-adjusted
| Metric | MYGN | NTLA |
|---|---|---|
| Price | $5.97 | $12.42 |
| Market cap | $571.0M | $1.74B |
| Today | −1.16% | +4.68% |
| 1 month | +39.5% | +0.4% |
| 6 months | +45.3% | −10.4% |
| Year to date | −2.9% | +38.1% |
| 1 year | −27.0% | −5.0% |
| Revenue growth (YoY) | −10.5% | −46.2% |
| Gross margin | 66.6% | 100.0% |
| Net margin | −22.7% | −1392.3% |
| P/E (TTM) | — | — |
| Price / sales | 0.7× | 29.2× |
| Net cash | -$5.5M | $437.8M |
| Dividend yield | — | — |
| Volatility (60d) | 85.1% | 63.3% |
| Short % of float | 10.1% | 38.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).